These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33419705)

  • 1. Sexual Motivation and Sexual Reward in Male Rats are Attenuated by the Gonadotropin-Releasing Hormone Receptor Antagonist Degarelix.
    Hawley WR; Kapp LE; Dingle CM; Dufala HA; Green PA; Barnes JL; Barwell JL
    J Sex Med; 2021 Feb; 18(2):240-255. PubMed ID: 33419705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of progesterone treatment during adulthood on consummatory and motivational aspects of sexual behavior in male rats.
    Hawley WR; Mosura DE
    Behav Pharmacol; 2019 Oct; 30(7):617-622. PubMed ID: 31033522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I. Antidepressants and sexual behavior: Weekly ketamine injections increase sexual behavior initially in female and male rats.
    Guarraci FA; Ali M; Gonzalez CMF; Lucero D; Clemons LW; Davis LK; Henneman EL; Odell SE; Meerts SH
    Pharmacol Biochem Behav; 2020 Dec; 199():173039. PubMed ID: 32926881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of an oxytocin receptor antagonist attenuates sexual motivation in male rats.
    Blitzer DS; Wells TE; Hawley WR
    Horm Behav; 2017 Aug; 94():33-39. PubMed ID: 28596135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sexual Incentive Motivation and Copulatory Behavior in Male Rats Treated With the Adrenergic α
    Lehtimäki J; Ventura-Aquino E; Chu X; Paredes RG; Ågmo A
    J Sex Med; 2021 Oct; 18(10):1677-1689. PubMed ID: 34493465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
    Cucchiara V; Yang JC; Liu C; Adomat HH; Tomlinson Guns ES; Gleave ME; Gao AC; Evans CP
    Mol Cancer Ther; 2019 Oct; 18(10):1811-1821. PubMed ID: 31341032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN; Woldu SL; Raj GV
    Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

  • 12. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of estrogen G-protein coupled receptor 30 (GPR30) and sexual experience in sexual incentive motivation in male rats.
    Hawley WR; Battista C; Divack SR; Morales Núñez NB
    Physiol Behav; 2017 Aug; 177():176-181. PubMed ID: 28472669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.
    Hopmans SN; Duivenvoorden WC; Werstuck GH; Klotz L; Pinthus JH
    Urol Oncol; 2014 Nov; 32(8):1126-34. PubMed ID: 25242517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food restriction dissociates sexual motivation, sexual performance, and the rewarding consequences of copulation in female Syrian hamsters.
    Klingerman CM; Patel A; Hedges VL; Meisel RL; Schneider JE
    Behav Brain Res; 2011 Oct; 223(2):356-70. PubMed ID: 21600244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial.
    Landgren V; Malki K; Bottai M; Arver S; Rahm C
    JAMA Psychiatry; 2020 Sep; 77(9):897-905. PubMed ID: 32347899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexual performance and precontact 50-kHz ultrasonic vocalizations in WAG/Rij rats: effects of opioid receptor treatment.
    Bialy M; Strefnel M; Nikolaev-Diak A; Socha A; Nikolaev E; Boguszewski PM
    Epilepsy Behav; 2014 Oct; 39():66-72. PubMed ID: 25216068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.